SCHEMBL6524942

SCHEMBL6524942

Clc1ccc2c(Cl)nc3ncccc3c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.45
NR4A2 P43354 2/20 0.44
ABCG2 Q9UNQ0 2/20 0.40
IGF1R P08069 1/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CCR1 P32246 1/20 0.39
CCR8 P51685 1/20 0.39
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.39
APEX1 P27695 1/20 0.39
MAPK1 P28482 1/20 0.39
PMP22 Q01453 1/20 0.39
TNKS O95271 1/20 0.38
HCAR2 Q8TDS4 4/20 0.38
ALDH1A1 P00352 1/20 0.38
ACHE P22303 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6527179 0.93 IDO1 (0.45) IDO1NR4A2ABCG2IGF1RMAPT
SCHEMBL3454517 0.84 HCAR2 (0.43) IDO1L3MBTL1MAPK1HCAR2ALDH1A1
SCHEMBL12786615 0.83 MAPT (0.48) IDO1ABCG2MAPTL3MBTL1CCR1
SCHEMBL6523544 0.81 HCAR2 (0.46) IDO1ABCG2MAPTLMNAHCAR2
SCHEMBL12786719 0.77 ABCG2 (0.60) ABCG2
SCHEMBL6520629 0.76 HCAR2 (0.45) ABCG2MAPTHCAR2ALDH1A1ACHE
SCHEMBL3454391 0.76 PDGFRB (0.46) IDO1ABCG2IGF1R
SCHEMBL3453991 0.75 RAB9A (0.41) IDO1ABCG2MAPTL3MBTL1LMNA
SCHEMBL6519039 0.73 NTRK1 (0.47) L3MBTL1MAPK1CDK1CDK5
SCHEMBL3453868 0.73 ABCG2 (0.44) IDO1ABCG2MAPTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 IDO1 4721/4885NR4A2 2584/4885ABCG2 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.